Progressive Myopia in a 9-Year-Old: When to Intervene
A 9-year-old girl has been followed for three years. Refractions (cycloplegic): age 6 = -1.25 DS OU; age 7 = -2.00 DS OU; age 8 = -2.75 DS OU; today = -3.50 DS OU with 0.75 D of against-the-rule astigmatism. Axial length has increased from 24.1 mm to 25.3 mm over the same period. She reads for several hours daily, spends about 1 hour outdoors on school days, and her parents are both myopic (-4.00 and -6.50). Corrected acuity is 20/20 OU, and binocular vision, cover test, and ocular health are normal. The parents have read about 'myopia control' online and ask whether their daughter is a candidate, and whether the options are safe.
1. Is this child a candidate for myopia control? Justify using the risk profile and the data provided.
Read the worked answer
Yes - she has multiple markers of fast progression and high ultimate myopia risk:
- Rate: roughly -0.75 D/year over three years, well above the ~-0.50 D/year typical of progressing juvenile myopia. Axial elongation of ~1.2 mm over three years (about 0.4 mm/year) corroborates genuine axial growth rather than crystalline lens change.
- Age: younger onset (already -1.25 D at age 6) predicts more years of progression before stabilization.
- Heredity: two myopic parents, one highly myopic, raises genetic risk.
- Environment: low outdoor time (~1 h/day) is a modifiable risk factor; higher near work adds modest risk.
Intervening now, while axial length is still increasing, offers the greatest chance to reduce final refractive error and axial length - the outcome most tied to later myopic maculopathy, retinal detachment, and glaucoma risk. The goal is slowing progression, not eliminating myopia. Baseline documentation (cycloplegic refraction, axial length, biometry) is essential to judge response at 6-12 months.
2. Compare the main myopia-control options for this child, including safety considerations, and outline how you would choose and monitor.
Read the worked answer
Options, with typical effect and safety:
- Low-dose atropine (0.01-0.05%) - roughly 50-60% slowing in trials; well tolerated. Risks: photophobia, near blur, allergic conjunctivitis; rare systemic effects. Requires punctal occlusion and clear dosing instructions.
- Orthokeratology - comparable slowing; reversible. Risks: microbial keratitis (rare but serious), so hygiene compliance and scheduled aftercare are mandatory; unsuitable for non-compliant children.
- Soft multifocal/dual-focus contact lenses - meaningful slowing in trials; risks similar to any soft lens (keratitis, hypoxia) with good hygiene.
- Outdoor time - about 1-2 hours/day is protective and low risk; recommend as an adjunct for all children.
Selection for this child: she is 9, motivated, with normal binocularity and health, so any option is plausible. I would discuss atropine and optical options, weigh family preference, compliance capacity, and cost, and avoid orthokeratology if hygiene is doubtful.
Monitoring: cycloplegic refraction and axial length every 6 months; if progression continues at >0.50 D/year on treatment, consider switching or combining. Review adverse effects at each visit and document the informed-consent discussion.